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Summary
The data presented in this paper describe trends in problem benzodiazepine use in 
Ireland. The paper describes treated problem benzodiazepine use as recorded by the 
National Drug Treatment Reporting System (NDTRS) for the years 2003–2008, and 
poisoning deaths where a benzodiazepine was implicated as recorded by the National 
Drug-Related Deaths Index (NDRDI) for the years 1998–2007. This is the first time that 
data from the NDTRS and the NDRDI have been presented together in a Trends Series 
paper. The presentation of these data together provides a more complete picture of 
problem benzodiazepine use and its consequences.
It is important to note that the NDTRS collects data on episodes of treatment in a 
calendar year, rather than on the individual person treated. This means that individuals 
may appear in the figures more than once if they receive treatment at more than one 
centre or at the same centre more than once a year. The NDRDI records and then 
matches data from four different sources on drug-related deaths and deaths among 
drug users and among those who are alcohol dependent.
The main findings from the analysis are:
In the period 2003–2008 the annual number of treated cases reporting a 
benzodiazepine as a problem substance increased by just over 63%, from 1,054 in 
2003 to 1,719 in 2008. 
For each case entering treatment the NDTRS records the main problem substance 
and up to three additional substances. The number of treated cases each year who 
reported a benzodiazepine as their main problem substance was relatively small, 
but increased by 120%, from 76 in 2003 to 167 in 2008. The number of cases who 
reported a benzodiazepine as an additional problem substance was much larger, and 
increased by 59%, from 982 in 2003 to 1,562 in 2008.
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The incidence of treated problem benzodiazepine use among the 15–64-year-old population living in 
Ireland increased from eight per 100,000 in 2003 to 19 in 2008. The number of new cases entering 
treatment is an indirect indicator of recent trends and points to an increase in benzodiazepine use over the 
six-year period. 
The prevalence of cases treated for problem benzodiazepine use among the 15–64-year-old population 
living in Ireland increased from 39 per 100,000 in 2003 to 56 in 2008. This indicates that problem 
benzodiazepine use is a chronic, recurring health condition that requires repeated episodes of treatment 
over time. 
The increase in the number of treated benzodiazepine cases may be explained by a combination of factors: 
an increase in the number of treatment places, an increase in problem benzodiazepine use among the 
population and an increase in reporting to the NDTRS. 
Between 1998 and 2007, benzodiazepines were implicated in nearly one third (31%) of all deaths by 
poisoning, with the annual number increasing from 65 in 1998 to 88 in 2007.
The annual rate of death by poisoning where a benzodiazepine was implicated increased from two per 
100,000 of the 15–64-year-old population in 2003 to three per 100,000 in 2006; the rate decreased 
slightly in 2007.
When the incidence of treated benzodiazepine cases was examined by place of residence, it was found 
that the rate differed depending on whether the benzodiazepine was reported as a main or an additional 
problem substance. Up until 2007, the incidence of cases reporting a benzodiazepine as their main 
problem substance was higher outside Dublin than in Dublin (city and county). However, for cases 
reporting a benzodiazepine as an additional problem substance, the incidence was consistently higher in 
Dublin than outside Dublin. 
When deaths were examined by place of residence, it was found that the annual death rate was consistently 
higher in Dublin than outside Dublin. 
The majority of cases (78%) treated for a benzodiazepine as their main problem substance reported the 
use of more than one problem substance. Alcohol was the most common additional problem substance, 
reported by 52% of cases, followed by cannabis (43%) and opiates (40%). The main problem substances 
reported where a benzodiazepine was the additional problem substance were opiates (80%) and, to 
a much lesser extent, alcohol (9%), cannabis (5%), and cocaine (5%). It is generally accepted that the 
use of several substances increases the complexity of these cases and is associated with poorer treatment 
outcomes.
The additional substances most frequently involved in poisoning deaths where a benzodiazepine was 
implicated were alcohol (41%) and methadone (36%).
Almost all treated cases (98%) reported taking benzodiazepines orally, and less than 1% reported injecting 
benzodiazepines. The number of cases reported as injecting benzodiazepines may be under-estimated 
because of the way the data are recorded by the NDTRS, whereby only one route of administration is 
recorded. The majority of cases (64%) reported using benzodiazepines daily. 
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The median age of new cases entering treatment for a benzodiazepine as their main problem substance 
decreased from 34 to 25 years over the reporting period, while the median age of previously treated cases 
remained stable, ranging between 27 and 29 years. The median age of cases entering treatment and 
reporting a benzodiazepine as an additional problem substance increased over the reporting period from 
24 to 26 years for new cases, and from 27 to 30 years for previously treated cases.
While numbers were small, the proportion of both new and previously treated cases who were aged under 
18 years increased over the six-year period. The proportion of under-18s was higher among cases reporting 
a benzodiazepine as their main problem substance (10%) than among cases reporting a benzodiazepine as 
an additional problem substance (4%). 
The median age of those who died as a result of poisoning where a benzodiazepine was implicated ranged 
between 33 and 39 years over the reporting period. Just over half (51%) were not alone at the time of their 
death. The majority of poisonings occurred in a private dwelling.
NDRDI and NDTRS data were further analysed by gender and age and, in the case of NDTRS data, by 
history of problem opiate use. 
Approximately 70% of all benzodiazepine cases treated in the period 2003–2008 were men and the 
proportion was the same for new cases and for previously treated cases. However, the male to female 
ratio differed depending on whether benzodiazepines were reported as a main or an additional problem 
substance. Over the six-year period, women accounted for 40% of cases with a benzodiazepine as their 
main problem and 30% of cases with a benzodiazepine as an additional problem substance.
Among those who reported a benzodiazepine as their main problem substance and who had no history of 
opiate use, there were higher proportions of female cases in the older age groups and higher proportions of 
male cases in the younger age groups. 
Similarly, among those who died, there were higher proportions of females in the older age groups and 
higher proportions of males in the younger age groups. 
The analysis has identified different groups within the population of problem benzodiazepine users. Age, 
gender, history of opiate use and whether benzodiazepines are a main or an additional problem substance 
are all factors that need to be considered within current service provision when treating this population. 
An online Appendix to this Trends Series paper, containing additional tables and figures with 
supplementary data from the NDTRS, is available on the National Documentation Centre on Drug Use 
website at www.drugsandalcohol.ie/14288
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Glossary
• Benzodiazepines constitute a group of some 33 chemically similar drugs which by depressing the 
central nervous system can reduce anxiety and/or induce sleep.
• Drug users: individuals who have a history of drug dependency or of non-dependent abuse of 
drugs and/or other substances
• Poisoning deaths: deaths which are directly due to the toxic effect of the presence in the body of 
one or more drugs and/or other substance(s)
• The median is the value at the mid–point in a sequence of numerical values ranged in ascending or 
descending order. It is defined as the value above or below which half of the values lie. Unlike the 
mean (average), the median is not influenced by extreme values (or outliers). For example, in the 
case of five drug users aged 22, 23, 24, 24 and 46 years respectively, the median (middle value) is 
24 years, whereas the mean is 27.8 years. While both the median and the mean describe the central 
value of the data, the median is more useful in this case because the mean is influenced by the one 
older person in this example. 
• Incidence is the number of new cases of disease or events that develop among a population during 
a specified time interval. As an example, in 2007, in a county with a population of 31,182, 10 opiate 
users sought treatment for the first time in 2007. The incidence is the number of new cases treated 
divided by the county population, expressed per given number of the population, i.e., per 100, per 
1,000, per 10,000, per 100,000 etc. 
The rate in this example may be calculated as follows: (10/31,182) x 100,000, which gives an incidence 
rate of 32 per 100,000 of the county population in 2007.
• Prevalence is the proportion of people in a population who have a disease or condition at a specific 
point or period in time. As an example, in 2007, in a county with a population of 31,182, 10 opiate 
users sought treatment for the first time, 20 returned to treatment and five continued in treatment 
from the previous year, giving a total of 35 people treated for problem opiate use in the year. The 
prevalence is the total number of cases divided by the county population, expressed per given 
number of the population, i.e., per 100, per 1,000, per 10,000, per 100,000 etc. 
The rate in this example may be calculated as follows: (35/31,182) x 100,000, which gives a prevalence 
rate of 112 per 100,000 of the county population in 2007.
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• Health Service Executive (HSE): Health care is provided through four HSE regions and 32 local 
health offices (LHOs). The local health offices are based on the geographical boundaries of the former 
community care areas. The table below presents the current HSE structure.
HSE regions Local health offices
HSE Dublin 
North East 
Dublin North West
Dublin North Central
Dublin North
Cavan/Monaghan
Louth
Meath
HSE Dublin 
Mid-Leinster 
Dublin South
Dublin South East
Dublin South City
Dublin South West
Dublin West
Kildare/West Wicklow
Wicklow
Longford/Westmeath
Laois/Offaly
HSE South 
Cork South Lee
Cork North Lee
West Cork
North Cork
Kerry
Carlow/Kilkenny
Tipperary South 
Waterford
Wexford
HSE West 
Donegal
Sligo/Leitrim/West Cavan
Galway
Mayo
Roscommon
Tipperary North/East 
Limerick
Limerick
Clare
• The data in this paper relating to the average annual incidence of treated problem substance use 
and place of residence of treated cases living in Ireland are presented by regional drugs task force 
areas. The 10 regional drugs task forces were created to service the areas covered by the former 
health boards.
In the case of data presented by region, this paper refers to the areas covered by the regional drugs task 
forces (RDTFs), together with the local drugs task forces (LDTFs) within their boundaries, as follows: 
Drugs task force Area included
ECRDTF
East Coast Regional Drugs Task Force 
(DTF)
South-east Dublin city and county and East Wicklow, 
including the two LDTF areas within these boundaries 
MRDTF Midland Regional DTF Counties Laois, Longford, Offaly and Westmeath
MWRDTF Mid West Regional DTF Counties Clare and Limerick, and North Tipperary
NDRDTF
North Dublin City and County Regional 
DTF
North Dublin city and county, including the five LDTF 
areas within these boundaries
NERDTF North Eastern Regional DTF Counties Cavan, Louth, Meath and Monaghan
NWRDTF North West Regional DTF Counties Donegal, Leitrim and Sligo, and north-west Cavan
SERDTF South East Regional DTF
Counties Carlow, Kilkenny, Waterford and Wexford, and South 
Tipperary,
SRDTF Southern Regional DTF Counties Cork and Kerry, including the Cork LDTF area
SWRDTF South Western Regional DTF
South-west Dublin, west Wicklow and County Kildare, 
including the six LDTF areas within these boundaries
WRDTF Western Region DTF Counties Galway, Mayo and Roscommon
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Acronyms
AIDS Acquired immune deficiency syndrome
CSO Central Statistics Office
CTL Central Treatment List
EMCDDA European Monitoring Centre for Drugs and Drug Addiction 
EU European Union
FSN Family Support Network
GMR General Mortality Register
GP General practitioner
HIPE Hospital In-Patient Enquiry scheme
HIV Human immunodeficiency virus
HRB Health Research Board
HSE Health Service Executive
LDTF Local drugs task force
MDMA 3,4-methylenedioxymethamphetamine, also known as ecstasy
NDRDI National Drug-Related Deaths Index
NDS National Drugs Strategy (interim) 2009–2016
NDTRS National Drug Treatment Reporting System
NHIS National Health Information Systems
RDTF Regional drugs task force
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Introduction
The benzodiazepine class of psychoactive drugs is one of the most commonly prescribed medications in 
the world.1 These drugs are used to treat a range of conditions, such as anxiety, insomnia and seizures.1-3 
Benzodiazepines are generally considered safe for short-term use; however, the risk of overuse, abuse and 
dependence when used for longer periods has been well documented.2 An overdose of benzodiazepine can 
cause respiratory depression, coma and death.2, 4 Benzodiazepines can also amplify the depressant effects of 
other drugs, including alcohol and opiates, so increasing the risk of overdose in polysubstance use.1-3 
A national drug prevalence survey in 2006/7 examined the use of sedatives and tranquillisers (which include 
benzodiazepines) in the adult population (aged 15–64) in Ireland (Table 1).5 Almost 11% of those surveyed 
reported having used such drugs at some point in their lives, with the proportion varying by age and by 
gender. Use was reported by a higher proportion of older adults (15%) than young adults (6%), and by a 
higher proportion of females (13%) than males (8%). The average age at first use was 29 years for males 
and 31 years for females. This survey also found that over half (57%) of those who had used sedatives or 
tranquillisers in the previous month (current users) had taken them daily. The survey did not record the 
type(s) of sedative and tranquilliser used.
Table 1 Prevalence of sedative and tranquilliser use in Ireland, 2006/7
Adults
15–64 years
%
Males
15–64 years
%
Females
15–64 years
%
Young adults
15–34 years
%
Older adults
35–64 years
%
Lifetime (ever used) 10.5 8.0 13.2 5.9 14.6
Last year (recent use) 4.7 3.7 5.7 2.5 6.5
Last month (current use) 3.0 2.4 3.5 1.3 4.4
Source: NACD and DPHIRB (2009)
The National Drug Treatment Reporting System (NDTRS) and the National Drug-Related Deaths Index 
(NDRDI) are epidemiological databases co-ordinated by the National Health Information Systems (NHIS) 
staff of the Health Research Board (HRB). The NDTRS records information on treated drug and alcohol 
misuse in Ireland on behalf of the Department of Health and Children. The NDRDI records information on 
drug- and alcohol-related deaths in Ireland on behalf of the Department of Health and Children and the 
Department of Justice and Law Reform. 
Background and Methods
National Drug Treatment Reporting System (NDTRS)
The monitoring role of the NDTRS was first recognised by the Government in the document Building on 
experience: National Drugs Strategy 2001–2008.6 The collection and reporting of data to the NDTRS was one 
of the actions identified and agreed by Government for implementation by the former health boards (now 
HSE regions). 
The National Drugs Strategy (interim) 2009–20167 (NDS) recognises the positive impact of the NDTRS on 
the development of key indicators, stating that ‘...the information provided through the NDTRS provide[s] 
significant insights into the patterns of problem drug use’, and that ‘drug treatment data has also improved 
substantially through the NDTRS…’ (p. 69). The NDS also recommends the continuation and further 
development of data-collection systems, including the NDTRS (Action 49). 
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The NDTRS was established in 1990 in the Greater Dublin Area and was extended in 1995 to cover all areas 
of the country. It was developed in line with the Pompidou Group’s Definitive Protocol8 and subsequently 
refined in accordance with the Treatment Demand Indicator Protocol.9 
Originally designed to record drug misuse, the NDTRS recorded problematic use of alcohol only in cases 
where it was an additional problem substance, that is, where the client’s main reason for entering treatment 
was drug misuse but he/she also reported problematic use of alcohol. In 2004, the remit of the NDTRS was 
extended to include cases where alcohol is recorded as the main or only reason for seeking treatment. The 
overlap between problem use of alcohol and that of other drugs has been identified in the strategic plans 
of a number of drugs task forces, which have emphasised the need for treatment services that can address 
the many forms of drug and polysubstance use.
Alcohol and other drug treatment data are viewed as an indirect indicator of drug and alcohol misuse, as 
well as a direct indicator of demand for treatment services. NDTRS data are used at national level (alcohol 
and drug data) and at European level (drug data) to provide information on the characteristics of clients 
entering treatment and on patterns of substance misuse, such as types of substance used and consumption 
behaviours. Drug data are ‘valuable from a public health perspective to assess needs, … and to plan and 
evaluate services’.10 
The HRB supplies service providers and policy makers with relevant data from the NDTRS to inform local 
and national substance misuse policy and planning. In recent years this information has been central to 
drug strategy and policy decisions: 
• In 1996 NDTRS data were used to identify a number of local areas with problematic heroin use.11 
These areas were later designated as local drugs task force (LDTF) areas, and task force teams have 
continued to provide strategic responses to drug misuse in their communities. 
• In 2004 NDTRS data were used to describe treatment-seeking characteristics and behaviours of those 
aged under 18 years and to inform the deliberations of the Working Group on treatment of under-
18-year-olds.12 
• In 2007 NDTRS data were used to inform some of the recommendations of the Working Group on 
drugs rehabilitation, and by the Working Group on residential services to help estimate the number 
of residential places required to address severe alcohol and drug problems in Ireland.13 
• In 2009 the Comptroller and Auditor General used data from the NDTRS in a special report which 
examined treatment and rehabilitation services provided for persons with drug addictions.14 
• In 2009 the NDS steering group used NDTRS data extensively to assess progress under the previous 
strategy.7 
Treatment for problem benzodiazepine use in Ireland is provided by statutory and non-statutory services, 
including residential centres, community-based addiction services, general practices and prison services. 
For the purpose of the NDTRS, treatment is broadly defined as any activity which aims to ameliorate the 
psychological, medical or social state of individuals who seek help for their substance misuse problems. 
Clients who attend needle-exchange services are not included in this reporting system. Treatment options 
for problem benzodiazepine use include one or more of the following: medication, psychiatric treatment, 
brief intervention, counselling (including cognitive behavioural therapy), medication-free therapy, family 
therapy, complementary therapy, and/or life-skills training.
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Compliance with the NDTRS requires that one form be completed for each new client coming for first 
treatment and for each previously treated client returning to treatment for problem substance use. Service 
providers at treatment centres throughout Ireland collect data on episodes of treatment, rather than on the 
individual person treated each year. HRB staff compile anonymous, aggregated data, which are analysed 
and reported at national and EU levels.
The main elements of the reporting system in the context of this paper are defined as follows: 
All cases treated – describes individuals who receive treatment for problem benzodiazepine use at each 
treatment centre in a calendar year, and includes: 
 – Previously treated cases – describes individuals who were treated previously for problem 
benzodiazepine or other drug use at any treatment centre and have returned to treatment for 
problem benzodiazepine use in the reporting year; 
 – New cases treated – describes individuals who have never been treated for problem benzodiazepine 
or other drug use; and
 – Status unknown – describes individuals whose status with respect to previous treatment for 
problem benzodiazepine or other drug use is not known.
In the case of the data for ‘previously treated cases’, there is a possibility that individuals appear more than 
once in the database, for example, where a person receives treatment at more than one centre or at the 
same centre more than once per year. 
National Drug-Related Deaths Index (NDRDI)
The NDRDI was established in September 2005 to comply with Action 67 of the 2001–2008 National Drugs 
Strategy.6 That action called for the development of a system for recording drug-related deaths and deaths 
among drug users to enable the State and its agencies to respond in a timely manner, with accurate data. 
The objectives of the NDRDI also include identifying and prioritising areas for intervention and prevention, 
and measuring the effects of such interventions.
The number of drug-related deaths and deaths among drug users is one of the key indicators used to 
measure the consequences of problem drug use in Europe. The NDRDI enables accurate reporting of these 
key data to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). The EMCDDA has 
recommended that all EU member states establish a special register to record these deaths. 
Data from the NDRDI were used to inform the current National Drugs Strategy7 and the development of 
the proposed National Overdose Prevention Strategy.
In order to ensure a complete and accurate database, the NDRDI records data from several sources: the 
Coroner Service, the Hospital In-Patient Enquiry scheme (HIPE), the Central Treatment List (CTL), the 
General Mortality Register (GMR) and the community representative body, Family Support Network (FSN) 
(still in the pilot phase). 
Cases from the different data sources are cross-matched on a selection of variables, including name, gender, 
county of residence, date of birth and date of death. This allows the NDRDI to eliminate duplicates and to 
maximise the amount of information available on each case recorded on the database. Named data were 
not available from the GMR for the period 1998 to 2005; to avoid duplication and over-estimation of the 
number of cases, GMR cases with no match are not included in the NDRDI for those years. 
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Drug use can lead to premature death from a range of causes.15 Many deaths are caused by poisoning 
(both intentional and unintentional), where the death is directly attributable to the consumption of drugs 
(alone or in combination with other substances). For the purposes of this paper, this type of directly drug-
related death is referred to as a poisoning. 
Deaths among drug users (whether the user is dependent or non-dependent) may be indirectly attributed 
to their drug use. For the purposes of this paper, this type of death is referred to as a non-poisoning. Causes 
of death in such cases include: 
• infection with HIV as a result of sharing drug paraphernalia, and subsequent development of an 
AIDS-related illness;
• the harmful effects of drug use (both short and long term) on the health of the drug user, such as 
the cardio-toxic effect of cocaine or drug-related liver disease;16-19 
• actions taken while under the influence of drugs, such as accidents caused by impaired judgement or 
exacerbation of risky behaviours;15, 16 
• psychiatric illness as a co-morbid condition, which places the individual at a greater risk of suicide.15, 20-22
In line with international practice, deaths which are the result of drug use by another individual, such 
as a road traffic accident or an assault, are not recorded by the NDRDI. A documented history of drug 
dependence or drug use is not available in all cases, leading to an under-recording of the total number of 
non-poisoning deaths in the drug-using population.
While the NDRDI has retrospectively recorded data from 2004 on alcohol-related deaths and deaths 
among those who are alcohol dependent, these data are not presented in this paper. Alcohol is included 
in the analysis presented in this paper only when it features as an additional addiction, and/or as part of a 
polysubstance finding in toxicology. 
Analysis
The data presented in this paper provide a description of treated problem benzodiazepine use in Ireland 
between 2003 and 2008. Data for the years 1998–2007 on poisoning deaths where benzodiazepines 
were implicated are also presented. This analysis does not include non-benzodiazepine sedatives such as 
zopiclone or zolpidem (known colloquially as ‘Z-drugs’). 
The analysis provides an outline of the following: 
• treatment provision;
• number of deaths;
• incidence and prevalence;
• place of residence;
• other substances used in conjunction with/or implicated with a benzodiazepine;
• patterns of use and socio-demographic characteristics of cases; and
• gender, age and history of opiate use of treated cases.
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Treatment provision
A total of 8,064 cases presented with a benzodiazepine as a problem substance in the six years 2003–2008, 
which represents 12.3% of all cases treated for problem substance use during that period. The HSE region 
of residence was known for 7,361 of those 8,064 cases. The following analysis excludes cases not normally 
resident in Ireland and cases whose HSE region of residence is not known. 
The total number of cases reporting a benzodiazepine as a problem substance (either as a main or an 
additional problem) increased by 63% in the six-year period, from 1,054 in 2003 to 1,719 in 2008 (Table 
2). The majority of benzodiazepine cases each year were treated in outpatient services, with the proportion 
ranging between 65% in 2004 and 82% in 2006. The number and proportion of benzodiazepine cases 
treated in inpatient services increased during the reporting period. The numbers of cases treated in low-
threshold and general practice settings were small and, in fact, decreased over the six-year period. In 2008, 
76% of all benzodiazepine cases were treated as outpatients and 20% as inpatients.
Table 2 All benzodiazepine cases entering treatment, by type of service provider (NDTRS 2003–
2008) 
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 1054 1026 1115 1222 1225 1719
Outpatient 788 (74.8) 666 (64.9) 855 (76.7) 998 (81.7) 830 (67.8) 1303 (75.8)
Inpatient 123 (11.7) 186 (18.1) 155 (13.9) 157 (12.8) 330 (26.9) 341 (19.8)
Low threshold 65 (6.2) 90 (8.8) 54 (4.8) 39 (3.2) 29 (2.4) 41 (2.4)
General practitioner 76 (7.2) 84 (8.2) 51 (4.6) 28 (2.3) 36 (2.9) 34 (2.0)
Provider not known 2 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Incidence and prevalence
Numbers treated for problem benzodiazepine use
The annual number of cases who reported a benzodiazepine as their main problem substance was small, 
but increased over the reporting period from 76 in 2003 to 167 in 2008 (Table 3). The number of cases 
who reported a benzodiazepine as an additional problem substance was much larger, and increased by 
59%, from 982 in 2003 to 1,562 in 2008.
Overall, the number of new cases in treatment increased by 169% over the period, from 214 in 2003 to 
576 in 2008, while the number of previously treated cases increased by 36%, from 816 to 1,113.
The number of new cases reporting a benzodiazepine as their main problem substance was small, but 
increased by 174%, from 27 cases in 2003 to 74 in 2008.
In the six-year period, the proportion of cases reporting a benzodiazepine as their main problem substance 
was higher among new cases (16%) than among previously treated cases (6%). Nearly half (48%) of cases 
reporting a benzodiazepine as their main problem substance were new cases.
Twenty-eight cases reported one type of benzodiazepine as their main problem substance and another 
type as an additional problem substance. Three-quarters of benzodiazepine cases treated in the years 
2003–2008 did not specify the type of benzodiazepine used. Of those who did specify the type, 77% used 
diazepam.
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Table 3 Benzodiazepine cases entering treatment, by treatment status (NDTRS 2003–2008)
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
All cases* 1054 1026 1115 1222 1225 1719
Benzodiazepine as a main 
problem 76 (7.2) 103 (10.0) 75 (6.7) 96 (7.9) 163 (13.3) 167 (9.7)
Benzodiazepine as an 
additional problem 982 (93.2) 928 (90.4) 1044 (93.6) 1129 (92.4) 1064 (86.9) 1562 (90.9)
Previously treated cases* 816 758 810 839 787 1113
Benzodiazepine as a main 
problem 49 (6.0) 50 (6.6) 30 (3.7) 40 (4.8) 72 (9.1) 87 (7.8)
Benzodiazepine as an 
additional problem 770 (94.4) 711 (93.8) 782 (96.5) 802 (95.6) 715 (90.9) 1032 (92.7)
New cases* 214 231 275 352 415 576
Benzodiazepine as a main 
problem 27 (12.6) 47 (20.3) 42 (15.3) 50 (14.2) 85 (20.5) 74 (12.8)
Benzodiazepine as an 
additional problem 188 (87.9) 186 (80.5) 235 (85.5) 302 (85.8) 332 (80.0) 505 (87.7)
Treatment status unknown 24 37 30 31 23 30
* The sum of ‘main problem’ and ‘additional problem’ cases may exceed the total number of cases in these treatment status 
categories as some cases reported one type of benzodiazepine as their main problem substance and another type of benzodiazepine 
as an additional problem substance.
Drug-related deaths where benzodiazepines were implicated
Between 1998 and 2007, benzodiazepines were implicated in 649 deaths, which accounted for 31% of all 
deaths by poisoning recorded by the NDRDI for the ten-year period (Table 4). 
The number of deaths in which benzodiazepines were implicated increased from 65 in 1998 to 88 in 2007. 
Almost all of the deaths (633, 98%) were polysubstance poisonings, implicating at least one other drug 
alongside a benzodiazepine. Of the 633 polysubstance deaths, a proportion involved more than one type 
of benzodiazepine: 113 (18%) involved two different types; and 13 (2%) involved three to four different 
types. 
Table 4 Percentage of poisonings where benzodiazepines were implicated (NDRDI 1998–2007) 
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Total poisonings 
(n = 2,120) 178 187 182 178 211 185 207 248 270 274
Benzodiazepines 
(n = 649)
65
(36.5)
56
(29.9)
61
(33.5)
47
(26.4)
61
(28.9)
54
(29.2)
63
(30.4)
66
(26.6)
88
(32.6)
88
(32.1)
History of drug treatment is not routinely recorded by all the data sources used by the NDRDI. 
Nevertheless, it was possible to ascertain that 174 (26.8%) of those who died in the ten-year period had 
received treatment for problem substance use at some point, and that 143 cases were in treatment for 
problem substance use at the time of their death.
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Annual rates
Annual rates for the incidence (new cases) and prevalence (all cases) of treated benzodiazepine use are 
expressed per 100,000 of the population aged 15–64 years, based on census figures for 2003 to 2006 and 
CSO estimated figures for 2007 and 2008.23, 24 
Figure 1 presents the annual incidence and prevalence rates of cases treated for a benzodiazepine as 
their main problem substance. The incidence increased from 1.0 in 2003 to 2.4 in 2008. The number 
of new cases entering treatment is an indirect indicator of recent trends and points to an increase in 
benzodiazepine use over the six-year period. The prevalence increased from 2.7 in 2003 to 5.4 in 2008. 
This indicates that problem benzodiazepine use is a chronic, recurring health condition that requires 
repeated episodes of treatment over time.
Figure 1 Incidence and prevalence of cases treated for a benzodiazepine as their main problem 
substance, per 100,000 of the 15–64-year-old population (NDTRS 2003–2008) 
Figure 2 presents the annual incidence and prevalence of cases treated for benzodiazepines as a main or 
an additional problem substance, alongside the rate of poisoning deaths where benzodiazepines were 
implicated (data not available for 2008). The prevalence of treated cases increased from 39 in 2003 to 
56 in 2008 and the incidence increased from eight in 2003 to 19 in 2008. The rate of death per 100,000 
increased between 2003 and 2006, but decreased slightly in 2007.
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Figure 2 Incidence and prevalence of all treated benzodiazepine cases and rate of death, per 
100,000 of the 15–64-year-old population (NDTRS 2003–2008 and NDRDI 2003–2007)
Place of residence
The annual numbers of treated benzodiazepine cases were analysed by place of residence, as in Dublin (city 
and county) or outside Dublin. Overall, 68% of benzodiazepine cases in the six-year period were living in 
Dublin at the time of entry into treatment. Just over half (51%) of new cases lived outside Dublin; the 
majority (75%) of previously treated cases lived in Dublin.
Table 5 presents new cases who reported benzodiazepines as a main or an additional problem substance, 
by place of residence. Three quarters (75%) of new cases reporting a benzodiazepine as their main 
problem substance lived outside Dublin, whereas the proportion of new cases reporting a benzodiazepine 
as an additional problem substance was higher in Dublin (54%).
Table 5 New benzodiazepine cases entering treatment, by place of residence (NDTRS 2003–2008)
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
New cases 214 231 275 352 415 576
Dublin 134 (62.6) 127 (55.0) 142 (51.6) 166 (47.2) 167 (40.2) 278 (48.3)
Outside Dublin 80 (37.4) 104 (45.0) 133 (48.4) 186 (52.8) 248 (59.8) 298 (51.7)
Benzodiazepine as a main problem 27 47 42 50 85 74
Dublin 5 (18.5) 13 (27.7) 7 (16.7) 10 (20.0) 22 (25.9) 23 (31.1)
Outside Dublin 22 (81.5) 34 (72.3) 35 (83.3) 40 (80.0) 63 (74.1) 51 (68.9)
Benzodiazepine as an additional 
problem 188 186 235 302 332 505
Dublin 129 (68.6) 114 (61.3) 135 (57.4) 156 (51.7) 146 (44.0) 255 (50.5)
Outside Dublin 59 (31.4) 72 (38.7) 100 (42.6) 146 (48.3) 186 (56.0) 250 (49.5)
In order to adjust for variation in population size, the annual incidence of treated benzodiazepine use was 
calculated by dividing the number of new cases living either in or outside Dublin by the population aged 
15–64 years living in the respective geographical areas, using the census figures for 2003 to 2006 and CSO 
estimated figures for 2007 and 2008.
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Up until 2007 the incidence of cases reporting a benzodiazepine as their main problem substance and 
living outside Dublin was consistently higher than that of cases living in Dublin (Figure 3). In 2008 the 
incidence of cases living in Dublin exceeded that of cases living outside Dublin.
Figure 3 Incidence of treated cases reporting a benzodiazepine as their main problem substance, 
by place of residence per 100,000 of the 15–64-year-old population (NDTRS 2003–2008) 
The incidence of cases reporting a benzodiazepine as an additional problem substance and living in 
Dublin was higher than the incidence of those living outside Dublin in each of the years examined (Figure 
4). The incidence of cases outside Dublin increased steadily over the six-year period, while the incidence in 
Dublin fluctuated in the years between 2003 and 2007 and peaked in 2008. The actual number of cases in 
Dublin almost doubled, rising from 129 in 2003 to 255 in 2008, and there was a fourfold increase in the 
number of cases outside Dublin, which rose from 59 in 2003 to 250 in 2008. 
Figure 4 Incidence of treated cases reporting a benzodiazepine as an additional problem substance, 
by place of residence per 100,000 of the 15–64-year-old population (NDTRS 2003–2008)
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The rate of deaths where benzodiazepines were implicated fluctuated over the reporting period. The rate of 
deaths per 100,000 of the adult population (aged 15–64) remained higher in Dublin than outside Dublin 
(Figure 5). However, the actual number of deaths in Dublin fell from 49 in 1998 to 41 in 2007, while 
outside Dublin the actual number of deaths rose from 15 in 1998 to 45 in 2007. 
Figure 5 Poisonings where benzodiazepines were implicated, by place of residence per 100,000 of 
the 15–64-year-old population (NDRDI 1998–2007)
Treatment and death data were further analysed by regional drugs task force (RDTF) area of residence. The 
numbers reported for each area may be influenced by treatment availability in the area, and by the extent 
to which services participated in the NDTRS.
Table 6 presents the number of new cases entering treatment in the period 2003–2007 who reported 
benzodiazepines as a problem substance, alongside the number of poisoning deaths where benzodiazepines 
were implicated, by RDTF area of residence. 
The highest numbers of new cases entering treatment were reported in the North Dublin, South West and 
Southern RDTF areas. The North West and Western RDTF areas reported the lowest numbers.
The annual numbers of poisoning deaths where benzodiazepines were implicated fluctuated over the 
reporting period, with no clearly discernable trends, in part due to the small numbers of cases in many 
of the RDTF areas. In the period 2003–2007 the highest numbers of deaths were recorded in the North 
Dublin, South West and Southern RDTF areas and the lowest numbers were in the North West and Western 
RDTF areas. This distribution pattern corresponds with the data on treated cases by RDTF area of residence. 
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Table 6 New benzodiazepine cases entering treatment, and poisoning deaths where 
benzodiazepines were implicated, by regional drugs task force area of residence (NDTRS 
and NDRDI 2003–2007) 
NDTRS 2003–2007 NDRDI 2003–2007
RDTF area of residence* n % n %
North Dublin City and County 423 28.4 78 21.7
South Western 302 20.3 65 18.1
Southern 282 19.0 67 18.7
South East 111 7.5 27 7.5
Mid West 90 6.1 23 6.4
North Eastern 69 4.6 13 3.6
Midland 66 4.4 18 5.0
East Coast 59 4.0 34 9.5
Western 45 3.0 14 3.9
North West 34 2.3 13 3.6
Address in Ireland unknown 6 0.4 7 2.0
Total 1487 100.0 359 100.0
* See glossary for details of counties/areas covered by each RDTF.
In order to adjust for variation in population size by geographical area, the incidence of treated 
benzodiazepine cases in each of the 10 RDTF areas was calculated by dividing the average number of 
new cases over the five-year period living in each of the areas by the population aged 15–64 years of the 
respective RDTF areas, using the census figures for 2003 to 2006 and CSO estimated figures for 2007.23, 24
Figure 6 presents the average annual incidence of cases reporting a benzodiazepine as their main problem 
substance, by RDTF area of residence. Figure 7 presents the average annual incidence of cases reporting a 
benzodiazepine as a main or an additional problem substance, also by RDTF area of residence.
For the period 2003–2007, the average annual incidence of new cases treated for a benzodiazepine as their 
main problem substance was highest in the Southern RDTF area at 3.6 cases per 100,000, followed by the 
South East, North Dublin and Mid West RDTF areas (Figure 6). The Western and East Coast RDTF areas had 
the lowest average annual incidence at less than one case per 100,000.
In the same period, the average annual incidence of benzodiazepine cases (main or additional problem 
substance) was highest in the North Dublin RDTF area at 23 cases per 100,000, followed by the South 
Western and Southern RDTF areas (Figure 7). The East Coast, North West and Western RDTF areas had the 
lowest average annual incidence at less than five cases per 100,000.
The incidence of treated benzodiazepine use was compared with the rate of poisoning deaths per 100,000 
population for the combined years 2003 to 2007 using the census figures for 2003 to 2006 and CSO 
estimated figures for 2007.23, 24
For the period 2003–2007, the highest rate of death per 100,000 population was in the North Dublin RDTF 
area at 4.0 cases per 100,000, followed by the Southern RDTF area at 3.1 cases per 100,000 (Figure 8). 
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Figure 6 Average annual incidence of cases treated for a benzodiazepine as their main problem 
substance per 100,000 of the 15–64-year-old population, by regional drugs task force 
area of residence (NDTRS 2003–2007)
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Figure 7 Average annual incidence of all treated benzodiazepine cases per 100,000 of the 
15–64-year-old population, by regional drugs task force area of residence (NDTRS 2003–
2007)
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Figure 8 Average annual rate of death by poisoning where benzodiazepines were implicated per 
100,000 of the 15–64-year-old population, by regional drugs task force area of residence 
(NDRDI 2003–2007)
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Additional substances used with benzodiazepine
The proportion of cases entering treatment who reported a benzodiazepine as their main problem 
substance and who also reported use of more than one problem substance fluctuated during the reporting 
period (Table 7). Overall, 78% of cases reported using more than one drug.
The proportion of new benzodiazepine cases reporting use of any additional problem substance decreased 
from 89% to 70% over the reporting period. The reverse was noted among previously treated cases. Within 
this group, the proportions reporting use of more than one substance rose from 67% in 2003 to 86% in 
2008. It is generally accepted that the use of several substances increases the complexity of these cases and 
is associated with poorer treatment outcomes. 
Table 7 Use of more than one drug by cases entering treatment who reported a benzodiazepine 
as their main problem substance, by treatment status (NDTRS 2003–2008)
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 76 103 75 96 163 167
All cases who used more than one 
drug 57 (75.0) 73 (70.9) 59 (78.7) 75 (78.1) 135 (82.8) 129 (77.2)
Previously treated cases 49 50 30 40 72 87
Previously treated cases who used 
more than one drug 33 (67.3) 45 (90.0) 23 (76.7) 33 (82.5) 64 (88.9) 75 (86.2)
New cases 27 47 42 50 85 74
New cases who used more than one 
drug 24 (88.9) 24 (51.1) 34 (81.0) 39 (78.0) 66 (77.6) 52 (70.3)
Treatment status unknown 0 6 3 6 6 6
Of the cases who reported a benzodiazepine as their main problem substance between 2003 and 2008, 
32% reported problem use of two substances, 22% of three and 23% of four or more. Cases with a 
benzodiazepine as their main problem substance most commonly reported two substances as part of their 
current problem substance use. The trends were similar for previously treated and new cases. 
Additional problem substances where 
benzodiazepines were the main problem substance
Table 8 presents the additional problem substances used by those who reported a benzodiazepine as their 
main problem substance and who used more than one drug. Between 2003 and 2008, alcohol was the 
most common additional problem substance, reported by 52% of cases, followed by cannabis (43%) and 
opiates (40%). 
The proportion of benzodiazepine cases reporting cannabis as an additional problem substance increased 
from 23% in 2003 to 49% in 2008, when it became the most commonly reported additional substance, on 
a par with alcohol at 48%. Over two-fifths of cases reported opiates as an additional problem substance in 
that year. 
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Overall, cannabis and alcohol were the most common additional problem drugs reported by new 
benzodiazepine cases entering treatment. The most frequently used additional problem substances reported 
by previously treated benzodiazepine cases in the period under review were opiates (55%), alcohol 
(47%) and cannabis (39%). 
Table 8 Additional problem substances used by cases entering treatment who reported a 
benzodiazepine as their main problem substance (NDTRS 2003–2008)
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 57 73 59 75 135 129
Opiates 20 (35.1) 46 (63.0) 19 (32.2) 24 (32.0) 50 (37.0) 54 (41.9)
Cocaine 7 (12.3) 20 (27.4) 18 (30.5) 18 (24.0) 38 (28.1) 33 (25.6)
Cannabis 13 (22.8) 24 (32.9) 28 (47.5) 32 (42.7) 65 (48.1) 63 (48.8)
Alcohol 34 (59.6) 24 (32.9) 35 (59.3) 46 (61.3) 72 (53.3) 62 (48.1)
Other* 18 (31.6) 28 (38.4) 14 (23.7) 17 (22.7) 34 (25.2) 38 (29.5)
Previously treated cases 33 45 23 33 64 75
Opiates 18 (54.5) 37 (82.2) 11 (47.8) 12 (36.4) 34 (53.1) 38 (50.7)
Cocaine 2 (6.1) 13 (28.9) 6 (26.1) 5 (15.2) 18 (28.1) 18 (24.0)
Cannabis 8 (24.2) 14 (31.1) 9 (39.1) 16 (48.5) 26 (40.6) 32 (42.7)
Alcohol 16 (48.5) 13 (28.9) 13 (56.5) 16 (48.5) 31 (48.4) 38 (50.7)
Other* 9 (27.3) 12 (26.7) 8 (34.8) 6 (18.2) 10 (15.6) 20 (26.7)
New cases 24 24 34 39 66 52
Opiates 2 (8.3) 8 (33.3) 7 (20.6) 10 (25.6) 15 (22.7) 15 (28.8)
Cocaine 5 (20.8) 6 (25.0) 12 (35.3) 12 (30.8) 19 (28.8) 14 (26.9)
Cannabis 5 (20.8) 8 (33.3) 19 (55.9) 13 (33.3) 35 (53.0) 31 (59.6)
Alcohol 18 (75.0) 10 (41.7) 21 (61.8) 29 (74.4) 37 (56.1) 24 (46.2)
Other* 9 (37.5) 16 (66.7) 6 (17.6) 11 (28.2) 21 (31.8) 16 (30.8)
Treatment status unknown 0 4 2 3 5 2
* Includes other licit and illicit substances such as ecstasy, amphetamines, other benzodiazepines and hypnotics, volatile inhalants and 
antidepressants.
Treated main problem substance where 
benzodiazepines were an additional problem substance
In the six-year period examined, the main problem substances reported where a benzodiazepine was an 
additional problem substance were opiates (80% of cases) and, to a much lesser extent, alcohol (9%), 
cannabis (5%) and cocaine (5%). This pattern of use was the same for new cases and previously treated 
cases; however the proportion of opiate users was much lower (63%) and the proportions of alcohol (16%) 
and cannabis (11%) users were higher among new cases.
The proportion of cases reporting opiates as their main problem substance and a benzodiazepine as an 
additional problem substance decreased from 92% in 2003 to 74% in 2008 (Table 9). During this period, 
although numbers were small, there was a sharp increase in cases reporting cocaine as their main problem 
substance and benzodiazepines as an additional problem substance.
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Table 9 Main problem substance used by cases entering treatment who reported a 
benzodiazepine as an additional problem substance (NDTRS 2003–2008)
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 982 928 1044 1129 1064 1562
Opiates 899 (91.5) 776 (83.6) 859 (82.3) 924 (81.8) 779 (73.2) 1155 (73.9)
Cocaine 19 (1.9) 37 (4.0) 35 (3.4) 54 (4.8) 69 (6.5) 93 (6.0)
Cannabis 50 (5.1) 21 (2.3) 40 (3.8) 47 (4.2) 59 (5.5) 123 (7.9)
Alcohol n/a 79 (8.5) 98 (9.4) 99 (8.8) 144 (13.5) 169 (10.8)
Other* 14 (1.4) 15 (1.6) 12 (1.1) 5 (0.4) 13 (1.2) 22 (1.4)
Previously treated cases 770 711 782 802 715 1032
Opiates 718 (93.2) 624 (87.8) 685 (87.6) 709 (88.4) 589 (82.4) 849 (82.3)
Cocaine 15 (1.9) 19 (2.7) 14 (1.8) 29 (3.6) 35 (4.9) 47 (4.6)
Cannabis 29 (3.8) 9 (1.3) 22 (2.8) 15 (1.9) 23 (3.2) 49 (4.7)
Alcohol n/a 49 (6.9) 57 (7.3) 45 (5.6) 61 (8.5) 78 (7.6)
Other* 8 (1.0) 10 (1.4) 4 (0.5) 4 (0.5) 7 (1.0) 9 (0.9)
New cases 188 186 235 302 332 505
Opiates 158 (84.0) 126 (67.7) 149 (63.4) 196 (64.9) 176 (53.0) 290 (57.4)
Cocaine 3 (1.6) 16 (8.6) 20 (8.5) 23 (7.6) 34 (10.2) 44 (8.7)
Cannabis 21 (11.2) 12 (6.5) 18 (7.7) 32 (10.6) 36 (10.8) 72 (14.3)
Alcohol n/a 27 (14.5) 40 (17.0) 50 (16.6) 80 (24.1) 87 (17.2)
Other* 6 (3.2) 5 (2.7) 8 (3.4) 1 (0.3) 6 (1.8) 12 (2.4)
Treatment status unknown 24 31 27 25 17 25
* Includes other licit and illicit substances such as ecstasy, amphetamines, other benzodiazepines and hypnotics, volatile inhalants 
and antidepressants.
n/a Not applicable, as alcohol was not recorded as a main problem substance prior to 2004.
Table 10 presents all drugs and other substances involved in cases of deaths by poisoning where 
benzodiazepines were implicated. Alcohol was the substance most frequently implicated in these deaths 
(41%), followed by methadone (an opiate) which was involved in over one third of cases (36%). As seen in 
the treatment data, although the numbers are small, the number of cases where cocaine was implicated in 
the cause of death in addition to benzodiazepines increased over the reporting period, from less than five 
cases in the years 1998–2003 to six cases in 2004 and to 13 cases in 2007.
Table 10 Additional drugs involved in poisonings where benzodiazepines were implicated (NDRDI 
1998–2007) (N = 649)
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 Total
n n n n n n n n n n n %
All deaths where a benzodiazepine 
was implicated* 62 54 61 46 61 54 61 66 88 89 642 100.0
Alcohol 21 19 19 20 25 28 27 30 33 39 261 40.7
Methadone 26 25 24 15 25 17 21 18 31 26 228 35.5
Other opiate (excluding heroin and 
methadone) 18 12 11 13 10 15 22 23 21 13 158 24.6
Antidepressants 9 7 16 13 10 12 25 18 22 13 145 22.6
Heroin 10 18 14 10 15 6 6 16 20 22 137 21.3
Benzodiazepine (additional types) 8 14 12 5 10 8 11 14 25 24 131 20.1
Other prescription medication 6 10 14 4 10 13 12 10 15 20 114 17.8
Cocaine ~ ~ ~ ~ ~ ~ 6 7 12 13 53 8.3
Other† 3 6 2 3 5 3 4 7 5 13 52 8.0
* Numbers and percentages in columns do not add up to totals shown in this row because individual deaths may be attributable to 
more than one drug or substance.
~ Less than five cases.
† Includes other illicit and licit drugs, including MDMA, amphetamines, hallucinogens, volatile inhalants and non-opiate analgesics.
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Patterns of treated problem benzodiazepine use
Taking benzodiazepine orally was the recorded method of administration for nearly all (98%) of 
the benzodiazepine cases who entered treatment between 2003 and 2008. In 2008, 100% of new 
benzodiazepine cases reported taking benzodiazepines orally, while less than one per cent of previously 
treated cases reported injecting benzodiazepines. The number of benzodiazepine injectors may be 
under-estimated because of the way the data are recorded by the NDTRS, whereby only one route of 
administration is recorded for each problem substance. Service providers therefore might record either 
the most common route of administration or the assumed route of administration. While the practice of 
smoking benzodiazepine-containing tablets that have been crushed into a powder has been reported and 
verified with service providers by HRB staff, this route of administration is seldom used and less than half of 
one per cent of cases in the six-year period reported smoking benzodiazepines.
The proportion of cases injecting benzodiazepines was higher among cases reporting a benzodiazepine as 
an additional problem substance (2%). Nearly 3% of previously treated cases reporting a benzodiazepine 
as an additional problem substance were injecting benzodiazepine at the time of entry into treatment. 
Among cases reporting a benzodiazepine as an additional problem substance, the proportion of injectors 
decreased over the period under review, from 5% in 2003 to 1% in 2008.
The majority of cases (64%) reported using benzodiazepines daily (Figure 9). In 2008, of the 167 cases 
who reported a benzodiazepine as their main problem substance, 61% used it daily, 15% used it between 
two and six days per week, 5% used it once per week or less, and 16% had not used it in the month prior 
to entering treatment. In the same year, the figure for ‘daily use’ was higher for new cases (65%) than for 
previously treated cases (55%).
Figure 9 Frequency of benzodiazepine use in the month prior to treatment for cases treated for a 
benzodiazepine as their main problem substance (NDTRS 2003–2008)
Between 2003 and 2008, the median age at which new cases reporting a benzodiazepine as their main 
problem substance commenced use of any drug was 15 years (Table 11). The median age at which new 
cases commenced benzodiazepine use was 20 years. Half of the new benzodiazepine cases had used 
benzodiazepines for six years or more before seeking treatment. 
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Table 11 Median age at significant points, and time in years between first use of benzodiazepines 
and entry into treatment, for new cases who reported a benzodiazepine as their main 
problem substance (NDTRS 2003–2008)
New cases
(n=325)
Age first used 
any drug 
(n=280)
Age first used 
benzodiazepines 
(n=284)
Age first sought 
treatment 
(n=325)
Years between first use 
of benzodiazepines 
and first seeking 
treatment (n=284)
Median age/time (range*) in years 15 (12–43) 20 (13–47) 28 (16–58) 6 (1–24)
* Age range presented is 5th percentile to 95th percentile (90% of cases are included within this range).
Socio-economic characteristics
Table 12 presents socio–economic characteristics of cases entering treatment who reported a 
benzodiazepine as their main problem substance, by treatment status. Table 13 presents the socio–
economic characteristics of cases who reported a benzodiazepine as an additional problem substance.
Of those entering treatment for a benzodiazepine as their main problem substance, the median age of 
new cases decreased from 34 to 25 years over the reporting period, while the median age of previously 
treated cases remained stable, ranging between 27 and 29 years (Table 12). 
The median age of cases entering treatment who reported a benzodiazepine as an additional problem 
substance increased both for new cases, from 24 to 26 years, and for previously treated cases, from 27 to 
30 years (Table 13).
While numbers were small, the proportion of cases aged under 18 years increased significantly over the 
six-year period, for both new and previously treated cases. The proportion of under-18s was higher among 
cases reporting a benzodiazepine as their main problem substance (10%) than among those for whom it 
was an additional problem substance (4%). Of those treated in 2008 for a benzodiazepine as their main 
problem substance, 16% of new cases and 12% of previously treated cases were under 18 years of age.
In the period 2003–2008, 6% of treated benzodiazepine cases reported being homeless. The proportion 
was the same for both those treated for a benzodiazepine as their main problem substance and those for 
whom it was an additional problem substance. 
In 2008, 20% of all cases reporting a benzodiazepine as their main problem substance had left school 
before the age of 15; the proportions were similar for new cases and previously treated cases, at 19% and 
20% respectively. 
In the same year, 7% of new cases were still at school and 14% were employed.
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Table 12 Socio-economic characteristics of cases entering treatment who reported a 
benzodiazepine as their main problem substance, by treatment status (NDTRS 2003–
2008)
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 76 103 75 96 163 167
Median age (range) 31 (18-56) 30 (18-57) 27 (16-56) 28 (16-60) 27 (16-51) 28 (16-59)
Under 18 years ~ ~ 10 (13.3) 11 (11.5) 20 (12.3) 22 (13.2)
Male 35 (46.1) 54 (52.4) 51 (68.0) 62 (64.6) 111 (68.1) 93 (55.7)
Living with parents and/or 
family 26 (34.2) 39 (37.9) 31 (41.3) 39 (40.6) 72 (44.2) 71 (42.5)
Homeless ~ 5 (4.9) ~ 7 (7.3) 16 (9.8) 6 (3.6)
Non-Irish national ~ ~ ~ ~ ~ 8 (4.8)
Early school leaver 15 (19.7) 21 (20.4) 19 (25.3) 18 (18.8) 27 (16.6) 33 (19.8)
Still at school 0 (0.0) ~ 6 (8.0) 6 (6.3) ~ 9 (5.4)
Employed (aged 16–64) 16 (21.3) 18 (17.6) 15 (20.3) 11 (12.5) 14 (8.8) 20 (12.4)
Previously treated cases 49 50 30 40 72 87
Median age (range) 29 (19-57) 27 (19-47) 27 (17-62) 27 (15-66) 28 (17-52) 29 (16-56)
Under 18 years ~ 0 (0.0) ~ ~ 5 (6.9) 10 (11.5)
Male 21 (42.9) 31 (62.0) 23 (76.7) 27 (67.5) 48 (66.7) 50 (57.5)
Living with parents and/or 
family 17 (34.7) 23 (46.0) 13 (43.3) 16 (40.0) 27 (37.5) 40 (46.0)
Homeless ~ ~ ~ ~ 6 (8.3) ~
Non-Irish national ~ ~ ~ ~ ~ ~
Early school leaver 7 (14.3) 10 (20.0) 10 (33.3) 9 (22.5) 9 (12.5) 17 (19.5)
Still at school 0 (0.0) 0 (0.0) 0 (0.0) ~ ~ ~
Employed (aged 16–64) 9 (18.8) 9 (18.0) 6 (20.7) 5 (13.9) 5 (6.9) 9 (11.0)
New cases 27 47 42 50 85 74
Median age (range) 34 (18-59) 34 (17-59) 27 (16-59) 29 (16-64) 27 (16-50) 25 (16-61)
Under 18 years 0 (0.0) ~ 8 (19.0) 7 (14.0) 12 (14.1) 12 (16.2)
Male 14 (51.9) 21 (44.7) 27 (64.3) 31 (62.0) 59 (69.4) 41 (55.4)
Living with parents and/or 
family 9 (33.3) 15 (31.9) 17 (40.5) 18 (36.0) 41 (48.2) 30 (40.5)
Homeless ~ ~ ~ ~ 8 (9.4) ~
Non-Irish national 0 (0.0) 0 (0.0) ~ ~ ~ 6 (8.1)
Early school leaver 8 (29.6) 8 (17.0) 8 (19.0) 8 (16.0) 16 (18.8) 14 (18.9)
Still at school 0 (0.0) ~ 6 (14.3) ~ ~ 5 (6.8)
Employed (aged 16–64) 7 (25.9) 9 (19.6) 9 (21.4) 6 (13.0) 9 (10.8) 10 (13.7)
Treatment status unknown 0 6 3 6 6 6
~ Less than five cases.
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Table 13 Socio-economic characteristics of cases entering treatment who reported a 
benzodiazepine as an additional problem substance, by treatment status 
(NDTRS 2003–2008)
2003 2004 2005 2006 2007 2008
n (%) n (%) n (%) n (%) n (%) n (%)
All cases 982 928 1044 1129 1064 1562
Median age (range) 26 (19-40) 27 (20-42) 28 (18-44) 29 (18-44) 28 (17-45) 28 (17-45)
Under 18 years 13 (1.3) 9 (1.0) 36 (3.4) 46 (4.1) 54 (5.1) 89 (5.7)
Male 674 (68.6) 642 (69.2) 716 (68.6) 797 (70.6) 768 (72.2) 1060 (67.9)
Living with parents and/or 
family 520 (53.0) 435 (46.9) 525 (50.3) 568 (50.3) 505 (47.5) 757 (48.5)
Homeless 56 (5.7) 62 (6.7) 59 (5.7) 68 (6.0) 66 (6.2) 94 (6.0)
Non-Irish national 25 (2.5) 18 (1.9) 19 (1.8) 23 (2.0) 25 (2.3) 45 (2.9)
Early school leaver 250 (25.5) 256 (27.6) 295 (28.3) 363 (32.2) 305 (28.7) 423 (27.1)
Still at school 8 (0.8) 1 (0.1) 16 (1.5) 7 (0.6) 12 (1.1) 36 (2.3)
Employed (aged 16–64) 121 (12.4) 111 (12.0) 119 (11.6) 97 (8.7) 113 (10.8) 148 (9.7)
Previously treated cases 770 711 782 802 715 1032
Median age (range) 27 (20-41) 28 (21-41) 28 (20-44) 29 (19-44) 29 (19-42) 30 (19-44)
Under 18 years 5 (0.6) ~ 17 (2.2) 18 (2.2) 14 (2.0) 25 (2.4)
Male 530 (68.8) 482 (67.8) 540 (69.1) 563 (70.2) 519 (72.6) 699 (67.7)
Living with parents and/or 
family 416 (54.0) 320 (45.0) 386 (49.4) 396 (49.4) 343 (48.0) 472 (45.7)
Homeless 43 (5.6) 47 (6.6) 46 (5.9) 48 (6.0) 56 (7.8) 67 (6.5)
Non-Irish national 17 (2.2) 13 (1.8) 10 (1.3) 12 (1.5) 19 (2.7) 31 (3.0)
Early school leaver 197 (25.6) 202 (28.4) 230 (29.4) 264 (32.9) 213 (29.8) 308 (29.8)
Still at school ~ 0 (0.0) 5 (0.6) ~ ~ 10 (1.0)
Employed (aged 16–64) 92 (12.0) 75 (10.5) 79 (10.2) 60 (7.6) 61 (8.6) 77 (7.6)
New cases 188 186 235 302 332 505
Median age (range) 24 (18-40) 25 (18-46) 25 (16-44) 27 (16-47) 26 (16-49) 26 (16-46)
Under 18 years 8 (4.3) 8 (4.3) 19 (8.1) 27 (8.9) 40 (12.0) 62 (12.3)
Male 126 (67.0) 138 (74.2) 154 (65.5) 216 (71.5) 239 (72.0) 347 (68.7)
Living with parents and/or 
family 93 (49.5) 100 (53.8) 124 (52.8) 159 (52.6) 157 (47.3) 278 (55.0)
Homeless 11 (5.9) 12 (6.5) 12 (5.1) 19 (6.3) 9 (2.7) 24 (4.8)
Non-Irish national 8 (4.3) ~ 9 (3.8) 10 (3.3) 6 (1.8) 14 (2.8)
Early school leaver 47 (25.0) 48 (25.8) 57 (24.3) 92 (30.5) 87 (26.2) 109 (21.6)
Still at school 6 (3.2) ~ 11 (4.7) ~ 11 (3.3) 25 (5.0)
Employed (aged 16–64) 23 (12.4) 34 (18.5) 37 (16.3) 34 (11.5) 51 (16.0) 68 (13.9)
Treatment status unknown 24 31 27 25 17 25
~ Less than five cases.
Table 14 presents socio–economic characteristics of poisoning deaths in the years 1998 to 2007 where 
benzodiazepines were implicated. 
The median age of those who died fluctuated over the ten-year period, ranging between 33 years and 
39 years. Overall, just over half (51%) of those who died were not alone at the time of their death. The 
majority of poisonings occurred in a private dwelling.
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Gender, age and history of problem opiate use
Studies have shown that there are some differences in age and gender in those who misuse 
benzodiazepines.1, 3, 25 In addition, problem benzodiazepine use among those who are also problem opiate 
users is well documented.26-28 Both NDRDI and NDTRS data were analysed by gender and by age and, in 
the case of NDTRS data, by history of problem opiate use. 
Approximately 70% of all benzodiazepine cases treated in the period 2003–2008 were men, and the 
proportion was the same for new cases and for previously treated cases. However, the male to female 
ratio differed depending on whether benzodiazepines were reported as a main or an additional problem 
substance. The male to female ratio was 6:4 for cases with a benzodiazepine as their main problem 
substance, and it was 7:3 for cases with a benzodiazepine as an additional problem substance. Over 
the six-year period, women accounted for 40% of cases with a benzodiazepine as their main problem 
substance and 30% of cases with a benzodiazepine as an additional problem substance.
Figure 10 presents a breakdown by age group and by gender of cases reporting a benzodiazepine as their 
main problem substance. Percentage figures show the age distribution within each gender. Female cases 
were more evenly distributed between age groups, particularly from the 25–29-year age group onwards. 
There were higher proportions of male cases in the younger age groups: 13% of men and 5% of women 
were under 18 years of age. There were higher proportions of females in the older age groups. Over one 
third (35%) of all women reporting a benzodiazepine as their main problem substance between 2003 and 
2008 were over 40 years of age, compared to 13% of men.
Figure 10 Cases entering treatment who reported a benzodiazepine as their main problem 
substance, by age group and by gender (NDTRS 2003–2008)
In terms of age and gender, the NDRDI data showed similar trends to those of the treatment data (Figure 
11). Of the total number of poisoning deaths where a benzodiazepine was implicated, the male to female 
ratio was 2:1. The proportion of male deaths was highest among the younger age groups. The proportion 
of female deaths increased in the age groups over 40. More than half (54%) of all female deaths between 
1998 and 2007 were aged 40 years or over, compared to 27% of male deaths.
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Figure 11 Poisoning deaths where benzodiazepines were implicated, by age group and by gender 
(NDRDI 1998–2007) (N = 649)
NDTRS data were further analysed by gender and by type of additional substances used. Table 15 presents 
the additional problem substances used by cases treated for a benzodiazepine as their main problem 
substance, by gender.
Alcohol was the most common additional problem substance reported by both men and women using a 
benzodiazepine as their main problem substance; the proportion was slightly higher among women (53%) 
than men (51%). However, the next most common additional problem substances reported by women 
were opiates (41%), other substances (31%, a third of which were another type of benzodiazepine) and 
cannabis (30%), whereas those reported by men were cannabis (49%), opiates (41%) and cocaine (33%).
Table 15 Additional problem substances used by cases entering treatment who reported a 
benzodiazepine as their main problem substance, by gender (NDTRS 2003–2008)
Male Female Gender not recorded
n (%) n (%) n (%)
All cases 341 183 4
Alcohol 175 (51.3) 97 (53.0) 1 (25.0)
Cannabis 169 (49.4) 55 (30.1) 1 (25.0)
Opiates 138 (40.5) 75 (41.0) 0 (0.0)
Cocaine 111 (32.6) 23 (12.6) 0 (0.0)
Other* 89 (26.1) 57 (31.1) 3 (75.0)
* Includes other licit and illicit substances such as ecstasy, amphetamines, other benzodiazepines and hypnotics, volatile inhalants and 
antidepressants.
Opiates were the main problem substance used by the majority of cases reporting a benzodiazepine 
as an additional problem substance, with the proportions of male and female cases almost equal, at 
approximately 80% (Table 16). Among those whose main problem substance was not an opiate, there was 
a difference between the proportions of male and female cases. A higher proportion of women (12%) than 
men (8%) reported alcohol as their main problem substance. Higher proportions of men than women 
reported cocaine and cannabis as their main problem substance.
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Table 16 Main problem substance used by cases entering treatment who reported a 
benzodiazepine as an additional problem substance, by gender (NDTRS 2003–2008)
Male Female Gender not recorded
n (%) n (%) n (%)
All cases 4657 2000 52
Opiates 3731 (80.1) 1617 (80.9) 44 (84.6)
Alcohol 349 (7.5) 237 (11.9) 3 (5.8)
Cannabis 280 (6.0) 59 (3.0) 1 (1.9)
Cocaine 245 (5.3) 60 (3.0) 2 (3.8)
Other* 52 (1.1) 27 (1.4) 2 (3.8)
* Includes other licit and illicit substances such as ecstasy, amphetamines, other benzodiazepines and hypnotics, volatile inhalants 
and antidepressants
Problem benzodiazepine use among opiate users has been documented in many studies.26-28 The NDTRS 
data were analysed by age and by gender to look at the history of opiate use among those who reported a 
benzodiazepine as their main problem substance. 
Overall, the majority (73.5%) of cases reporting a benzodiazepine as their main problem substance did not 
report use of an opiate. Among non-opiate users there were higher proportions of male benzodiazepine 
cases in the younger age groups. The majority (51%) of male cases were aged under 25 years, compared 
to 24% of female cases. There were higher proportions of female cases in the older age groups: over half 
(53%) of female cases were over 35 years of age, compared to 24% of male cases. However, among opiate 
users, the age distribution was similar for both males and females.
Table 17 Cases entering treatment who reported a benzodiazepine as their main problem 
substance, by age group, gender and opiate use (NDTRS 2003–2008)
Male Female Gender not recorded
n (%) n (%) n (%)
Not an opiate user 292 204 4
17 years or under 49 (16.8) 13 (6.4) 1 (25.0)
18–19 37 (12.7) 9 (4.4) 0 (0.0)
20–24 62 (21.2) 27 (13.2) 1 (25.0)
25–29 43 (14.7) 20 (9.8) 1 (25.0)
30–34 30 (10.3) 25 (12.3) 0 (0.0)
35–39 27 (9.2) 24 (11.8) 1 (25.0)
40–44 14 (4.8) 29 (14.2) 0 (0.0)
45–49 15 (5.1) 22 (10.8) 0 (0.0)
50 years or over 14 (4.8) 34 (16.7) 0 (0.0)
Age not recorded 1 (0.3) 1 (0.5) 0 (0.0)
Opiate user 114 66 0
17 years or under ~ 0 (0.0) 0 (0.0)
18–19 6 (5.3) ~ 0 (0.0)
20–24 24 (21.1) 15 (22.7) 0 (0.0)
25–29 38 (33.3) 16 (24.2) 0 (0.0)
30–34 20 (17.5) 14 (21.2) 0 (0.0)
35–39 12 (10.5) 7 (10.6) 0 (0.0)
40–44 7 (6.1) ~ 0 (0.0)
45–49 ~ 6 (9.1) 0 (0.0)
50 years or over ~ 0 (0.0) 0 (0.0)
Age not recorded 0 (0.0) 1 (1.5) 0 (0.0)
~ Less than five cases.
Further tables and figures with supplementary NDTRS data for this Trends Series paper are available in an 
online appendix at www.drugsandalcohol.ie/14288
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Conclusions
This is the first time that data from the NDTRS and the NDRDI have been presented together in a Trends 
Series paper. The presentation of these data together allows different aspects of problem benzodiazepine 
use to be examined to build a more complete picture of the burden of this problem. 
The number of cases entering treatment for problem benzodiazepine use, as either a main or an 
additional problem substance, increased steadily between 2003 and 2008. The highest numbers of cases 
consisted of those previously treated who reported a benzodiazepine as an additional problem substance.
Differences were noted in the incidence of treated cases depending on whether the client lived in or outside 
Dublin (city and county). Up until 2007, the incidence of cases reporting a benzodiazepine as their main 
problem substance was higher outside Dublin. However the incidence of cases reporting benzodiazepines 
as an additional problem substance was higher in Dublin over the six-year reporting period. This may 
reflect differences in access to treatment or differences in patterns of drug use. Most benzodiazepine cases 
(74%) were treated in outpatient services. 
The majority of cases treated for problem benzodiazepine use were also using another drug or substance, 
most frequently opiates, alcohol and cannabis. Alcohol was the most common additional problem 
substance reported by cases using a benzodiazepine as their main problem substance; 80% of cases 
reporting a benzodiazepine as an additional substance were opiate users. This is significant as it is 
generally accepted that the use of several substances increases the complexity of these cases and is 
associated with poorer treatment outcomes. Problem use of benzodiazepines needs to be approached in 
the context of multiple substance use. The types of intervention and treatment setting very much depend 
on the individual’s current problem substances and history of substance use and the treatment services 
available in the HSE area.
Benzodiazepines were implicated in almost one third of all deaths by poisoning in Ireland between 1998 
and 2007. Almost all of the deaths involved polysubstance use, which reflects international trends showing 
that benzodiazepine-only poisonings occur but are rare.15, 29 The most frequently implicated additional 
substances were alcohol and opiates (methadone, heroin and other opiates). This pattern of benzodiazepine 
use was reflected in the treatment data, where most cases used a benzodiazepine in combination with 
other substances, particularly alcohol and opiates. Alone, these substances may not be sufficient to cause 
death, but it is likely that the respiratory depressant effect is amplified when these substances are taken 
together, increasing the risk of fatal overdose. The combination of substances with benzodiazepines, 
especially when it includes opiates such as methadone, in fatal poisonings has frequently been reported in 
international studies.15, 30-32 
The increasing number of cases in treatment and the number of deaths among the population support the 
findings of the most recent national drug prevalence study, which showed that 11% of all adults had used 
sedatives or tranquillisers (which include benzodiazepines) at some point in their lives.5 A study in the west 
of Ireland showed that the number of prescriptions for benzodiazepines had increased annually between 
2000 and 2007.33 Although beyond the scope of this paper, it would be useful to examine the number of 
benzodiazepine prescriptions provided nationally in order to have a clearer view of the nature and extent of 
the issue.
33Problem benzodiazepine use in Ireland: treatment (2003 to 2008) and deaths (1998 to 2007)
A very small proportion of treated cases reported injecting benzodiazepines; many of these were 
previously treated cases who reported a benzodiazepine as an additional problem substance. The 
national population survey found that only 0.5% of those who used sedatives or tranquillisers injected 
them, and that all who did inject were male.5 However, the survey data do not reflect the finding of 
the recent longitudinal drug treatment study that 13% of those entering opiate treatment had injected 
benzodiazepines.28 It is likely, then, that the number of cases injecting benzodiazepines is under-estimated 
in the NDTRS.
Although the numbers were small, the proportion of cases under 18 years of age increased steadily 
between 2003 and 2008. The proportion was highest in those who presented with a benzodiazepine 
as their main problem substance. This finding has implications for health promotion, drug awareness 
campaigns and service provision for this vulnerable age group. 
Among those who reported a benzodiazepine as their main problem substance, there were higher 
proportions of female cases in the older age groups and higher proportions of male cases in the younger 
age groups. Similarly, among those who died, there were higher proportions of females in the older age 
groups and higher proportions of males in the younger age groups. 
The analysis presented in this paper has identified different groups within the population of problem 
benzodiazepine users. Age, gender, history of opiate use and whether benzodiazepines are a main or an 
additional problem substance are all factors that need to be considered within current service provision 
when treating this population. As previously stated, there needs to be a greater awareness among 
prescribers and users of the potentially fatal effects of benzodiazepines in polysubstance use. Identifying and 
controlling possible illicit sources of benzodiazepines is also necessary, but it is equally important to revisit 
the good practice and prescribing guidelines for doctors.34
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